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Abstract
Background: The EURIKA study aims to assess the status of primary prevention of cardiovascular disease (CVD) across 
Europe. Specifically, it will determine the degree of control of cardiovascular risk factors in current clinical practice in 
relation to the European guidelines on cardiovascular prevention. It will also assess physicians' knowledge and 
attitudes about CVD prevention as well as the barriers impeding effective risk factor management in clinical practice.
Methods/Design: Cross-sectional study conducted simultaneously in 12 countries across Europe. The study has two 
components: firstly at the physician level, assessing eight hundred and nine primary care and specialist physicians with 
a daily practice in CVD prevention. A physician specific questionnaire captures information regarding physician 
demographics, practice settings, cardiovascular prevention beliefs and management. Secondly at the patient level, 
including 7641 patients aged 50 years or older, free of clinical CVD and with at least one classical risk factor, enrolled by 
the participating physicians. A patient-specific questionnaire captures information from clinical records and patient 
interview regarding sociodemographic data, CVD risk factors, and current medications. Finally, each patient provides a 
fasting blood sample, which is sent to a central laboratory for measuring serum lipids, apolipoproteins, hemoglobin-
A1c, and inflammatory biomarkers.
Discussion: Primary prevention of CVD is an extremely important clinical issue, with preventable circulatory diseases 
remaining the leading cause of major disease burden. The EURIKA study will provide key information to assess 
effectiveness of and attitudes toward primary prevention of CVD in Europe. A transnational study creates opportunities 
for benchmarking good clinical practice across countries and improving outcomes. (ClinicalTrials.gov number, 
NCT00882336.)
Background
Despite important progress in prevention and treatment,
the epidemic of cardiovascular disease (CVD) in Europe
is far from controlled. With over 4.3 million deaths per
year, CVD is the foremost cause of death across Europe
and the leading cause of disability adjusted life years [1].
Both CVD mortality and its trends vary within Europe.
The incidence of and mortality from coronary heart dis-
ease (CHD) is declining in various countries in Northern
and Central Europe, where the risk of CVD has been
highest for several decades. In contrast, CHD mortality
has been falling less rapidly, and is even increasing in
Eastern Europe. In the Mediterranean area, the recent
decline in morbidity has been more moderate, although
from a background of lower mortality [1]. In these coun-
tries, the growth and progressive ageing of the population
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in recent years have led to the paradoxical situation of
reduced age-adjusted CHD mortality on the background
of an increased number of deaths which tend to occur
later in life and, consequently, a greater burden of disease
and disability [2]. This paradoxical increase in the popu-
lation burden of CHD is emerging even in countries with
marked reductions in age-adjusted CHD mortality, such
as England and Wales [3].
There is a large and compelling body of evidence on the
efficacy of primary CVD prevention [4], and of its popu-
lation impact. For example, in several European countries
most of the reduction in CHD mortality in recent
decades has been due to interventions focusing on reduc-
ing the impact of classic CVD risk factors, at the popula-
tion level or in individual patients in clinical practice [5-
7]. However, the vast residual burden of CVD suggests
that there is an important unmet need for primary CVD
prevention in Europe.
Primary cardiovascular prevention in clinical practice in 
Europe
The majority of information available on the manage-
ment of risk factors for CVD in clinical practice is limited
to patients with established CVD or with very high CVD
risk such as those with diabetes mellitus. Several studies
such as the REACH registry or EUROASPIRE have
shown a high prevalence of undertreated CVD risk fac-
tors (particularly those related to lifestyle) among outpa-
tients and hospitalized patients with atherothrombosis
[8,9]. It is both notable and disappointing that, despite the
advances in the evidence base, global risk factor control
seems to have improved little in these high risk patients
since 1995 [10].
The EPA Cardio project is evaluating the quality of
CVD prevention in primary care in 10 European coun-
tries; however, it only studies higher risk patients (over
10% risk of death from CVD in 10 years or at least 3 CVD
risk factors) [11]. Thus, there is little information in
Europe on the clinical management of CVD risk factors
across the whole spectrum of primary prevention. In par-
ticular, it is not known whether patients are being man-
aged in accordance with recent European guidelines on
CVD prevention [4]. A central element in these guide-
lines is the measurement of global CVD risk according to
the SCORE equation [12], and adjustment of the intensity
of the intervention to the magnitude of the risk. Although
a previous edition of the European guidelines recom-
mended calculation of CVD risk with the SCORE [13],
there has been no comprehensive assessment of the
extent of use of formal risk assessment systems, the selec-
tion of risk assessment tools and the use of such estimates
of risk by European physicians in clinical decision-mak-
ing.
A better understanding of these issues is key for design-
ing interventions to overcome the barriers preventing
implementation of the European guidelines on CVD pre-
vention.
Barriers impeding the use of global cardiovascular risk and 
the adoption of other recommendations from the 
European guidelines for CVD prevention
Just over 10 years ago, Cabana and colleagues proposed a
model to explain the reasons why physicians do not fol-
low clinical practice guidelines [14]. These reasons
included lack of awareness of existing guidelines, lack of
familiarity with them, disagreement with some aspect of
the guidelines, lack of self-efficacy performing a certain
behavior, or the presence of external barriers such as lim-
ited resources (time, physical space, reimbursement for
procedures, etc.)
Some studies in Europe have examined physicians'
knowledge and attitudes about CVD prevention, espe-
cially in primary care. However, these studies were often
small [15,16], focused on control of only a single risk fac-
tor such as dyslipidaemia [17], or provided data limited to
a single country [18]. Thus, in contrast to the knowledge
available in the United States of America (USA) [19,20],
there is no comprehensive European picture of the barri-
ers impeding effective control of CVD risk factors and
reducing adherence to the recommendations of European
guidelines for primary CVD prevention. However, the
rich mix within Europe in the organization of National
health care systems, in material resources, in academic
training of physicians and in patients' cultural and socio-
economic backgrounds provides an opportunity to learn
about the most favorable conditions for primary CVD
prevention. Although many of the existing barriers are
likely to operate at the local level and are likely to require
more local solutions, a standardized, contemporaneous
trans-national comparison creates an opportunity to
emulate those clinical practices that work well in other
countries.
The role of new biomarkers in dyslipidaemia management
Improved reduction of cholesterol levels in persons free
from CVD is one of the factors that has contributed most
to the decline in CHD mortality in some European coun-
tries [5,6] and in the USA [21]. Consequently, it seems
reasonable to optimize control of cholesterol to reduce
residual CVD risk, with low density lipoprotein (LDL)
cholesterol the principal therapeutic target in lipid man-
agement. However, a recent practice guideline suggests
the use of alternative biomarkers, such as non high den-
sity lipoprotein (HDL) cholesterol (total cholesterol
minus HDL cholesterol) or apolipoprotein-B (apo B) to
monitor the effects of lipid-lowering treatment, especially
in patients who have already reached low or moderateRodríguez-Artalejo et al. BMC Public Health 2010, 10:382
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levels of LDL cholesterol but also have various other car-
diometabolic risk factors [22], particularly elevated trig-
lycerides. Unlike LDL cholesterol, measurement of non-
HDL cholesterol and apo B does not require overnight
fasting. In addition, both biomarkers are better predictors
of CVD risk than LDL cholesterol, especially in patients
treated with statins [23,24]. Therapeutic goals have
recently been proposed for non-HDL cholesterol and apo
B [22]. However, data are lacking on the effectiveness of
dyslipidaemia management based on these biomarkers,
and thus on the opportunities therefrom for reducing the
residual CVD risk associated with dyslipidaemia.
In addition, chronic low grade inflammation is known
to contribute to the development and progression of
atherothrombosis; furthermore, one marker of inflamma-
tion, high sensitivity C-reactive protein (hs-CRP), is a
modest but consistent predictor of CVD events [25]. The
recent JUPITER study has shown that rosuvastatin
reduces major CVD events and all-cause mortality in
patients without elevated LDL cholesterol but with mod-
estly elevated hs-CRP [26]. This is important because
many people who develop acute myocardial infarction or
stroke are apparently healthy and have cholesterol levels
and global risk scores below the thresholds for more
intensive preventive treatment.
Most trans-national studies on the clinical manage-
ment of dyslipidaemia in primary CVD prevention have
been based on medical record reviews and on interviews
with physicians and patients [11,15,17,27], but lacked
contemporary biological data such as fasting blood sam-
ples. Thus, previous studies in this area have been unable
to assess levels and model the impact of emerging bio-
markers such as non-HDL cholesterol, apo B and hs-CRP,
since these tests were not routinely performed.
Study objectives
The European Study on Cardiovascular Risk Prevention
and Management in Usual Daily Practice (EURIKA) is an
international research initiative conducted in 12 Euro-
pean countries. Its overall aim is to assess the status of
primary CVD prevention in the clinical setting across
Europe. The specific aims are to determine the degree of
CVD risk factor control according to the updated Euro-
pean guidelines on CVD prevention [4], and to identify
the systems used and barriers faced by physicians in con-
trolling CVD risk factors as well as their attitudes towards
this aspect of their current clinical practice. Blood sam-
ples are also collected from EURIKA study participants to
measure and explore the role of novel biomarkers for
identification of patients at increased risk of CVD who
might benefit from more intensive interventions.
Methods/Design
Design
The EURIKA study is a multinational, cross-sectional
study conducted in 12 countries (Austria, Belgium,
France, Germany, Greece, Norway, Russia, Spain, Swe-
den, Switzerland, Turkey, and the United Kingdom) (fig-
ure 1). These countries were selected to represent the
whole spectrum of CVD risk, risk factor control, and
organization of health-care services across Europe. Data
collection started in May 2009 and was completed in Jan-
uary 2010. All participating patients provided signed
informed consent The study protocol has been approved
by the appropriate clinical research ethics committees in
each participating country, and complies with the local
regulations for clinical research. In particular the proto-
col was approved by the following ethics committees:
Ethics Committee of Hospital Barmherzige Brüder,
Vienna, Austria; Ethics Committee University Hospital,
Ghent. Belgium; National Commission on Informatics
and Liberties, Paris, France; Ethics Committee of the
Friedrich-Alexander-University Erlangen-Nuremberg,
Germany; Scientific Council of University General Hos-
pital of Ioannina, and the National Organization for Med-
icines - EOF), Greece; Regional Committee for Ethics in
Medicine and Research Sor-?st B (REK Sor-?st B, Oslo,
Norway; Independent Interdisciplinary Ethics Commit-
tee, Moscow, Russia; Clinical Research Ethics Committee
of La Paz University Hospital, Madrid, Spain; Ethics
Committee of the University hospital of Linköping, Swe-
den; Ethics Committee for Ambulatory Clinical Research.
Medical Association of Geneva, Switzerland; Research
Ethics Committee of Medical Faculty, Gazi University,
Ankara, Turkey; Brent Primary Care Trust applied
research unit, National Health Service, London, UK
Study participants
The study sample was selected in a two-step process that
involved recruitment of physicians and their outpatients.
Physicians were selected to represent current practitio-
ners in primary care centers or outpatient clinics involved
in CVD prevention in each country. Rosters of practicing
physicians in each country were obtained from the
OneKey database, a large database containing informa-
tion on the characteristics of practicing physicians (table
1) http://www.cegedim.com/corporate/cegedim_eng/
cegedimdendrite.htm. This database was used to select a
random sample of physicians stratified by age, sex and
specialty, including family medicine and other medical
specialties involved in CVD risk factor control, such as
cardiology, internal medicine, and endocrinology. Physi-
cian sex and age strata are proportional to their distribu-
tion in the OneKey database. To determine the
proportion of practitioners in each medical specialty
invited to participate, we followed the advice of key prac-
ticing physicians in each country who were interviewed
about local characteristics of the health care system and
the participation of each type of medical specialist in
CVD prevention. Based on their responses, the propor-
tion of physicians in each specialty varies across coun-
tries, although family physicians working at the primaryRodríguez-Artalejo et al. BMC Public Health 2010, 10:382
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care level predominate in all countries. The EURIKA
study includes approximately 60 physicians per country
(table 2). The percentage of participating physicians
among those invited is 7.9% for the whole study (range
3.1% in Sweden to 22.8% in Turkey).
We selected patients aged 50 years or older with at least
one CVD risk factor who attended for routine consulta-
tion with the participating physicians. The CVD risk fac-
tors comprising the inclusion criteria are described in
table 3. Patients with a history of a previous CVD event,
defined as myocardial infarction, angina (stable or unsta-
ble), stroke, or transient ischemic cerebrovascular event
were excluded, as well as patients already participating in
a clinical trial. All participating patients provided signed
informed consent.
Patients who met the selection criteria were randomly
selected by the attending physician. The sample size is
approximately 600 patients per country for a total study
population of 7,641 patients. A sample size of 600 sub-
jects allows for estimating the prevalence of risk factor
control with a 95% confidence interval of 5% for an
expected control prevalence of 50% (worst possible case)
and a risk factor prevalence of 50%. Table 4 shows the
participating patients by sex, age and country. The per-
centage of participating patients among those invited was
60.1% for the whole study (range 48.2% in Germany to
77.9% in Norway). Though patients were asked about rea-
sons for not participating, in most cases they did not pro-
vide any or simply reported that they had no interest or
time to participate.
Study variables and methods of data collection
Information was collected prospectively at both the phy-
sician and the patient level. A physician specific question-
naire captured information regarding physician
demographics, practice settings, cardiovascular preven-
tion beliefs and management. A patient-specific ques-
tionnaire captured information from clinical records and
patient's interview, regarding sociodemographic data,
CVD risk factors, current medications, comorbidity, and
others aspects of CVD prevention and management
Anthropometry and blood pressure readings were
obtained under standardized conditions for each patient.
Both physician and patient-level questionnaires were
translated into local language.
A fasting blood sample was obtained on the same day as
the outpatient consultation or, if this was not possible, on
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the following day. With the exception of Russia, where
laboratory determinations were performed locally, the
blood samples were sent to a central laboratory in Bel-
gium (The Bio Analytical Research Corporation, http://
www.barclab.com, Belgium) for assessment of serum lip-
ids, apo AI, apo B, hs-CRP, uric acid, and creatinine.
Additionally, serum samples were stored at -70°in a cen-
tral biobank (BARCLAB, Gent, Belgium), only for future
determination of emergent CVD biomarkers.
Table 5 includes a full description of data collection
methods and study variables in the EURIKA study. In
each country, a 10% random sample of all centres with
participating physicians underwent a site visit for data
monitoring and audit, to ensure data quality.
Statistical analysis
The main analyses will be conducted according to a sta-
tistical plan drafted before completion of data collection.
Statistical analyses will address the main study objectives.
Accordingly, estimates of control of CVD risk factors will
be provided for each country, by sex, age group (50-64
years, 65 years and older) and 10-year risk of CVD death
(below 5%, 5% or more). The cut-points defining control
o f  e a c h  r i s k  f a c t o r  w i l l  b e  t a k e n  f r o m  t h e  E u r o p e a n
Guidelines on CVD prevention [4]; for estimates of dys-
lipidaemia control based on apo B and non-HDL choles-
terol, we will use the cut-points agreed in the consensus
statement from the American Diabetes Association and
the American College of Cardiology Foundation [22]. The
ris k  of  CVD dea t h will  be  ca lcula t ed wit h t he  SCO RE
equation; for Belgium, France, Greece, Spain and Turkey
using the SCORE equation for low-risk regions, while the
equation for high-risk regions will be used for partici-
pants from Austria, Germany, Norway, Russia, Sweden,
Table 2: Physicians* participating in the EURIKA study, by sex, age and country
Sex Age
Total Men Women < 50 years ≥ 50 years
N N (%) N (%) N (%) N (%)
Austria 62 40 (64.5) 22 (35.5) 22 (35.5) 40 (64.5)
Belgium 78 57 (73.1) 21 (26.9) 56 (71.8) 22 (28.2)
France 55 37 (67.3) 18 (32.7) 18 (32.7) 37 (67.3)
Germany 66 48 (72.7) 18 (27.3) 25 (37.9) 41 (62.1)
Greece 63 41 (65.1) 22 (34.9) 45 (71.4) 18 (28.6)
Norway 57 39 (68.4) 18 (31.6) 41 (71.9) 16 (28.1)
Russia 93 13 (14.0) 80 (86.0) 64 (68.8) 29 (31.2)
Spain 70 37 (52.9) 33 (47.1) 35 (50.0) 35 (50.0)
Sweden 57 42 (73.7) 15 (26.3) 16 (28.1) 41 (71.9)
Switzerland 71 55 (77.5) 16 (22.5) 39 (54.9) 32 (45.1)
Turkey 68 55 (80.9) 13 (19.1) 57 (83.8) 11 (16.2)
United Kingdom 69 48 (69.6) 21 (30.4) 44 (63.8) 25 (36.2)
Total 809 512 (63.3) 297 (36.7) 462 (57.1) 347 (42.9)
*General medicine/family medicine, internal medicine, cardiology, and endocrinology.




N N (%) N (%)
Austria 9848 5772 (58.6) 4076 (41.4)
Belgium 12588 8527 (67.7) 4061 (32.3)
France 69173 49448 (71.5) 19725 (28.5)
Germany 74963 47740 (63.7) 27223 (36.3)
Greece 11699 8131 (69.5) 3568 (30.5)
Norway 6181 3931 (63.6) 2250 (36.4)
Russia 54592 6798 (12.5) 47794 (87.5)
Spain 69266 31726 (53.5) 27540 (46.5)
Sweden 8740 5099 (58.3) 3641 (41.7)
Switzerland 8093 5980 (73.9) 2113 (26.1)
Turkey 39825 27053 (67.9) 12772 (32.1)
United Kingdom 44330 26085 (58.8) 18245 (41.2)
Total 399298 226290 (56.7) 173008 (43.3)
*General medicine/family medicine, internal medicine, 
cardiology and endocrinology.Rodríguez-Artalejo et al. BMC Public Health 2010, 10:382
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Switzerland and the United Kingdom [13]. Ancillary anal-
yses might use SCORE equations calibrated with the
national prevalence of CVD risk factors and CVD mortal-
ity rates in those countries where available, or country-
specific CVD risk equations such as QRISK2 from the
United kingdom[28].
The same type of descriptive statistical approach will be
used for data on barriers faced by physicians in control-
ling CVD risk factors, as well as their knowledge of and
attitudes toward CVD prevention.
Discussion
We expect the EURIKA study to provide important infor-
mation to quantify the degree of control of CVD risk fac-
tors and to identify barriers to successful CVD
prevention in Europe, both at the physician and patient
Table 4: Patients participating in the EURIKA study, by sex, age and country
Sex Age
Total Men Women < 65 years ≥ 65 years
N N (%) N (%) N (%) N (%)
Austria 624 297 (47.6) 327 (52.4) 402 (64.4) 222 (35.6)
Belgium 638 312 (48.9) 326 (51.1) 342 (53.6) 296 (46.4)
France 593 325 (54.8) 268 (45.2) 329 (55.5) 264 (44.5)
Germany 678 333 (49.1) 345 (50.9) 309 (45.6) 369 (54.4)
Greece 620 285 (46.0) 335 (54.0) 380 (61.3) 240 (38.7)
Norway 611 298 (48.8) 313 (51.2) 373 (61.1) 238 (38.9)
Russia 604 192 (31.8) 412 (68.2) 492 (81.5) 112 (18.5)
Spain 642 330 (51.4) 312 (48.6) 383 (59.7) 259 (40.3)
Sweden 628 315 (50.2) 313 (49.8) 324 (51.6) 304 (48.4)
Switzerland 667 352 (52.8) 315 (47.2) 325 (48.7) 342 (51.3)
Turkey 663 313 (47.2) 350 (52.8) 511 (77.1) 152 (22.9)
United Kingdom 673 344 (51.1) 329 (48.9) 349 (51.9) 324 (48.1)
Total 7641 3696 (48.4) 3945 (51.6) 4519 (59.1) 3122 (40.9)
Table 3: Criteria to include patients in the EURIKA study
1. Age 50 years or older
2. Free of clinical cardiovascular disease
3. At least one of the following cardiovascular risk factors (as assessed from the most recent data in the clinical record or anthropometry 
for obesity)
a) Dyslipidaemia - LDL cholesterol ≥ 4.1 mmol/l (160 mg/dl), or
- HDL cholesterol < 1.036 mmol/l (40 mg/dl) in men, and < 1.30 
mmol/l (50 mg/dl) in women, or
- Triglycerides ≥ 1.7 mmol/l (150 mg/dl), or
- Under lipid-lowering medication
b) Hypertension - Systolic blood pressure ≥ 140 mm Hg, or
- Diastolic blood pressure ≥ 90 mm Hg, or
- Under antihypertensive medication
c) Smoking - Current or former smoker, with > 100 cigarettes smoked in lifetime
d) Diabetes mellitus - Fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dl), or
- Under antidiabetic medication (insulin or oral medications)
e) Obesity - Body mass index ≥ 30 kg/m2, or
- Waist circumference ≥ 102 cm in men and ≥ 88 cm in womenRodríguez-Artalejo et al. BMC Public Health 2010, 10:382
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level. The transnational setting of EURIKA will also cre-
ate opportunities for benchmarking good clinical practice
across countries.
A potential limitation of the EURIKA study is the lack
of a comprehensive framework for physician sampling in
all European countries. W e used the OneKey database,
which is the largest available database of practicing physi-
cians in Europe, although not statistically representative
of all European physicians. As a further limitation, the
participation rate among invited physicians was not opti-
mal. It is possible that physicians more competent in
CVD prevention were more likely to agree to participate;
in this case, the results of EURIKA study could provide a
best-case scenario that may slightly overestimate the con-
trol of CVD risk factors and quality of care in usual clini-
cal practice. Nevertheless, the large number of
practitioners included, the coverage of all relevant medi-
cal specialties and work-settings, and the random selec-
tion of study patients, suggest that the EURIKA study is
likely to provide a comprehensive picture of the status of
primary CVD prevention across Europe, which is as
accurate as practically possible.
As additional strengths, the EURIKA study has used
standardized procedures for data collection according to
a common protocol for all countries. The questionnaire
was easy to complete, and data abstracted from clinical
records refer to basic and frequently assessed clinical
v a r i a b l e s ,  m a n y  o f  t h e m  f r o m  l a b o r a t o r y  t e s t s  r e p r e -
sented in the inclusion criteria. Also, blood samples have
been analyzed with the same methods in a central labora-
tory, and a biobank has been set up for future studies.
Most of the questions physicians were asked regarding
knowledge and attitudes about CVD prevention were
based on previously field-tested questionnaires. More-
over, as each physician had to report on only a few
patients, questionnaire burden has been minimized.
Lastly, assessment of control of CVD risk factors is based
on objective measures (blood pressure readings, anthro-
pometry, and laboratory results) specifically obtained for
the EURIKA study. Thus, data quality in the EURIKA
study is likely to exceed that of studies relying solely on
data abstraction from clinical records and interviews.
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Table 5: Data collection methods and main study variables in EURIKA
Collection method Variables
Questionnaire addressed to the physician Academic training, work-setting and other characteristics of the physicians
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- Knowledge, attitudes, and practices of physicians regarding cardiovascular prevention 
and management
- For every patient, information on management of cardiovascular risk (frequency of 
cardiovascular risk factors assessment, lifestyle counselling, therapeutic goals, treatment 
adherence).
Questionnaire addressed to patients, and 
clinical record abstraction
Patients' demographic and psychosocial characteristics
- Relevant family medical history: early cardiovascular event
- CVD risk factors related to lifestyle (tobacco smoking, physical activity)
- Comorbidity
Current medication: antihypertensives, statins and other lipid-lowering drugs, oral 
antidiabetics, insulin, anticoagulants, aspirin, and combination drug therapy
Laboratory results taken from the clinical 
record (most recent blood data and physical 
examination during the previous year)
- Total cholesterol, LDL cholesterol, HDL cholesterol, non-HDL cholesterol, triglycerides, 
blood pressure, hemoglobine-A1c
Measurements performed on patients during 
the medical visit
Weight, height, waist and hip circumference, and blood pressure, under standardized 
conditions
Blood sample collected during the medical 
visit
- Total cholesterol, LDL cholesterol, HDL-cholesterol, non-HDL cholesterol, triglycerides, 
apolipoprotein B, apolipoprotein AI, hemoglobine-A1c, high-sensitivity C-reactive protein, 
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